FDA approves avapritinib in PDGFRA-mutated gastrointestinal tumors

In January 2020, the FDA approbed avaprintinib for the treatment of metastatic gastrointestinal stromal tumors (GIST).  This drug is approved for GIST tumors that harbor a specific mutation in FDGFRA gene.  This gene mutation usually indicates a very resistant tumor to normal medications. Trials have shown a high response rate with almost 85% seeing tumor shrinkage.  Side effects may include nausea, fatigue, memory loss and edema.

Click for more information